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INTRODUCTION
The former Soviet Union's first nuclear bomb test was conducted at the Semipalatinsk Nuclear Test Site (SNTS), located in the northeast part of the Republic of Kazakhstan, on 29 August 1949. During the following 40 years, there were 456 nuclear explosions including atmospheric and surface events between 1949 and 1962. 1) As a result, it is suspected that several hundreds of thousands of residents near the SNTS in Kazakhstan were considered to be exposed to radiation. Considerable efforts have been made to assess the radiation doses and effect of ionizing radiation on population residing around the SNTS, [2] [3] [4] [5] [6] [7] [8] [9] and it is well known that solid cancers (esophagus, stomach, liver, lung, breast and thyroid) [10] [11] [12] [13] and leukemias 14) occur more frequently among residents near the SNTS than in the general population. However, there is no study of other hematological disease such as myelodysplastic syndrome (MDS).
Hematological diseases among the atomic bomb survivors in Hiroshima and Nagasaki have been analyzed well. [15] [16] [17] Acute and chronic leukemias among atomic-bomb survivors appeared after a minimum latency period of 2-3 years, reached a maximum after 6-7 years, decreased slowly with time and then returned to the background level after 30 years. 18) But other hematological malignancies increased after long minimum latency periods of 10 or more years, continued to increase with time, and are still high, even now, more than 60 years after exposure, having similar kinetics to cancers. This hematological disease is MDS that is an umbrella term for a heterogeneous collection of hematopoietic stem cell disorders affecting elder adults. 19) MDS is a distinct group of clonal hematopoietic disorders charac-terized by ineffective hematopoiesis, refractory cytopenias and a tendency to progress into acute myeloid leukemia (AML). 19) Most of the patients found to have MDS are older than 60 years of age. A substantial proportion of MDS arises in the setting of exposures to radiation including atomic bomb, occupational toxins or cytotoxic therapy for a prior malignancy. So far, previous study analyzed gene mutations in hematological diseases among atomic bomb survivors in Hiroshima and found a high mutation frequency of the AML1 gene in MDS/AML patients. 20) The AML1 gene encodes a transcriptional factor essential for hematopoiesis and its alterations are the causes of hematological malignancies. 21) Previous studies reported that AML1 point mutations were also frequent among radiation-associated and therapy-related MDS or AML. 20, 22, 23) These studies indicate that exposure to radiation may have an effect on the development of MDS through mutations of the AML1 gene.
In this study, we tried to analyze mutations of the AML1 gene in the patients with hematological malignancies especially MDS among the residents near the SNTS. Our study is a kind of a pilot study to reveal the hematological effects caused by the nuclear tests on the residence near the SNTS.
MATERIALS AND METHODS

Patients
We examined patients with hematological diseases diagnosed at Semipalatinsk Emergency Hospital and UstKamenogorsk City Hospital, located in the vicinity of the SNTS, from 1999 to 2007. Patients diagnosed at Astana City Hospital, who were defined as not exposed to ionizing radiation and living in the control area of Astana, were also examined. These patients were diagnosed according to the French-American-British (FAB) classification 24) as acute myeloid leukemia (AML), acute lymphoid leukemia (ALL), chronic myeloid leukemia (CML) and myelodysplastic syndrome (MDS). MDS patients were subdivided into refractory anemia (RA), RA with excess blasts (RAEB) and RAEB in transformation (RAEBt). Three disease categories corresponding to subgroups of MDS and AML (i.e., RAEB, RAEBt and AML following MDS) were identified as MDS/ AML.
22)
Estimation of the individual effective doses of the patients
The total effective doses from external irradiation and thyroid doses from internal irradiation for the average residents of these settlements were estimated previously.
2) By using this method, we tried to estimate the individual effective dose of each patient by taking into account the residential region and birth year of the patients. All patients near the SNTS were divided into four radiation dose groups according to their total effective doses: (1) high level group (greater than 300 mSv), (2) middle level group (50 to 300 mSv), (3) low level group (0.1 to 50 mSv), and (4) negligible level group (less than 0.1 mSv). Patients born long after atmospheric or surface nuclear explosions were classified in the negligible group.
DNA extraction
After gaining informed consent and ethics committee approval, genomic DNA was extracted from smear slides of bone marrow by using QIAamp DNA Micro Kit (Qiagen GmbH, Hilden, Germany) as manufacturer's protocol. Briefly, a dried bone marrow smear was soaked with Tissue Lysis Buffer and was scraped off the slide glass. After treatment with Proteinase K, DNA was eluted with Lysis Buffer and was purified with QIAamp MinElute Column.
Identification of AML1 mutations
The mutation analysis of AML1 exons 3 through 8 was performed by polymerase chain reaction-single-strand conformation polymorphism (PCR-SSCP) as described previously. 22) Briefly, the 1 μl of genomic DNA extractions were amplified by PCR using the 6 pair of flanking intronic, forward/reverse primers. To identify the AML1 mutations, SSCP analysis was performed on a GenePhor system (Amersham Pharmacia Biotech, Buckinghamshire, England). For each abnormal band, genomic DNA was reamplified and the PCR products were directly sequenced in both directions.
Identification of N-RAS, c-KIT, p53 and FLT3 mutations
Mutation analysis of other genes was performed as described previously. 25) The polymerase chain reaction (PCR) amplified the DNA sequence of interest: exons 1 and 2 of N-RAS; 26) exons 8 and 17 of c-KIT; 27) exons 5-8 of p53 28) and internal tandem duplication (ITD) and the D835 mutation of FLT3. 29, 30) Amplicons were checked by agarose gel electrophoresis to make sure that only the specific product was amplified and to find additional bands indicating ITD of FLT3. Screening for D835 mutations of FLT3, amplicons were digested with EcoRV before the electrophoresis. Gene mutations were screened by PCR-SSCP for c-kit (exon 8), or denaturing high performance liquid chromatography (DHPLC) analysis for N-RAS (exons 1 and 2), c-kit (exon 17) and p53 (exons [5] [6] [7] [8] . DHPLC was performed on a WAVE DNA fragment analysis system (Transgenomic, Omaha, NE). For each abnormal elution profile, genomic DNA was re-amplified and the PCR products were directly sequenced.
RESULTS
We got a total of 125 samples of the patients with hematological diseases. There were 73 cases from the hospitals in the vicinity of SNTS, including 36 cases of acute myeloid To estimate the individual effective doses, the living places of the patients around SNTS were examined minutely. Thirtyfour cases were from Semipalatinsk City; 9 cases from the Beskaragaiskii district (Semiyarka village, Bolshaya Vladimirovka village, Novo-Nicolaevka village, Dolon village); 3 cases from the Abralinskii district (Kainar village); 6 cases from the Abai district (Sarzhal village, Karaul village); 2 cases from the Zhana-Semey district (Znamenka village, Mukur village); 1 case from the Borodulihinskii district (Boroduliha village); 1 case from the Novoshulbinskii district (Shulbinsk town); 1 case from the Maiskii district (Akzhar village); 2 cases from the Ayaguzskii district (Ayaguz town); 9 cases from Ust-Kamenogorsk City; 1 case from Leninogorsk City; 3 cases from the Shemonaiha district (Shemonaiha town, Serebryanka village) and 1 case from Zyryanovsk City. All patients had been living for their entire life in their birth place or the surrounding districts within the SNTS. According to the estimated individual effective dose, 73 patients with hematological disease among the residence near the SNTS were divided into 4 dose groups, as shown in Table 1 . Fifty-two patients from the control area of Astana had never lived near SNTS and were classified as an unexposed group.
We analyzed exons 3 through 8 of the AML1 gene by PCR-SSCP assay using genomic DNA and confirmed mutations by sequence analysis. AML1 point mutations were identified in 7 patients, all of them with MDS/AML. We observed equal intensities of normal and shifted bands in the PCR-SSCP analysis of AML1 mutations, it was suggested that mutations of AML1 gene were monoallelic (Fig. 1) . No AML1 mutation was found in the patients with MDS (RA), AML, ALL and CML.
The frequency of AML1 mutations in radiation-exposed MDS/AML patients were compared with that in unexposed MDS/AML patients. As shown in Table 2 , 25 of MDS/AML patients near SNTS (age 52.1 ± 16.9 years) and 13 of patients in Astana (age 52.5 ± 12.9 years) were divided into 5 dose groups according to their estimated individual dose. A total of 18 patients in high, medium and low dose groups were regarded as radiation-exposed patients (age 60.8 ± 11.7 years). Negligible dose and unexposed groups were regarded as controls, but patients in the negligible dose group were too young (age 31.3 ± 7.0 years) to be compared with exposed patients because they were born long after atmo- spheric or surface nuclear explosions. Therefore, we selected 13 patients with MDS/AML from Astana as the unexposed controls. AML1 point mutations were detected in 7 of 18 (39%) radiation-exposed MDS/AML patients. In contrast, no AML1 mutation was found in 13 cases of unexposed MDS/AML. The distributions of the patients were in the vicinity of radioactive fallout trace of 4 major nuclear events (Fig. 2) . AML1 mutations were identified in 2 patients of the high dose group (> 300 mSv) affected by #4 nuclear event and in 5 of 11 patients of the low dose group (0.1-50 mSv), but not detected in the medium dose group. The frequency of AML1 mutations in radiation-exposed patients with MDS/AML was significantly higher compared with unexposed patients (p < 0.05, Fisher's exact probability test). Furthermore, we examined a correlation between the individual dose of radiation and AML1 mutations in MDS/AML patients and found a significant correlation between dose and AML1 mutations (p < 0.05) but no correlation between age and mutations (p > 0.1, Spearman's correlation coefficient by rank test).
To investigate additional genetic alternations in patients with MDS/AML, we analyzed the N-RAS, FLT3, c-KIT and p53 genes. We found 3 N-RAS mutations and one FLT3 mutation, but no p53 and c-KIT mutations in radiationexposed patients with MDS/AML. One patient in the low dose group had both N-RAS mutation and AML1 mutation. One p53 mutation was detected in a patient in the negligible dose group.
DISCUSSION
In this study, we have demonstrated that AML1 mutations were frequently detected in radiation-exposed MDS/AML patients among the residents near the SNTS. These results suggested that radiation might contribute to the development of MDS/AML through AML1 mutations among the residents near the SNTS. Furthermore, a significant association between AML1 mutations in MDS/AML patients and an individual radiation dose was detected.
The AML1 gene has been known to be frequently mutated in MDS/AML patients among atomic bomb survivors and radiation therapy-related MDS/AML patients. 20, 22, 23) Our study showed that radiation-exposed patients with MDS/ AML near SNTS also had a high frequency of the AML1 gene mutations. We also found a significant correlation between individual estimated doses and AML1 mutations. Considering these results, AML1 point mutations might be a specific biomarker that differentiates radio-induced MDS/ AML from spontaneous MDS/AML.
As for the radiation effects among the residents around SNTS, previous epidemiologic studies have shown a significantly increased risk of solid cancers [10] [11] [12] [13] and leukemias. 14) Moreover, some molecular studies revealed high frequency of chromosome aberrations 31) or mutations of T-cell receptor in lymphocytes 32) and high prevalence of ret/PTC rearrangements in patients with thyroid cancers among these resi- 8) dents. 33) High frequencies of these abnormalities in the molecular level are considered to be a cause of the significant increases of malignancies. Thus, we suspect that high frequency of AML1 mutations in MDS/AML might show an increased risk of MDS/AML in SNTS. But it is difficult for us to mention the incidence of MDS/AML in this area, because this study analyzed a very small number of the patients because of a hospital-based study. Although MDS has not been well investigated partly because of difficulties in differential diagnosis from other hematological diseases, much more attention should be paid to MDS/AML as a late effect of radiation among the residents near the SNTS. Further epidemiological studies are necessary to confirm these speculations.
Another question arose from this study. MDS/AML patients in the negligible dose group were relatively young at MDS diagnosis. In general, MDS is rare before the age of 50 years. This is consistent with the theory of spontaneous genetic mutations that are more likely to occur as people grow older. Although these patients in the negligible dose group had no AML1 mutation, there might be some molecular biological effects on the residents born long after the nuclear tests in the highly contaminated area. Further mutation analysis is necessary to resolve this question.
In conclusion, we found a high frequency of AML1 point mutations in MDS/AML patients near SNTS. The AML1 mutations are considered as a useful biomarker of radiationinduced MDS/AML because this study showed a correlation between individual radiation dose and AML1 mutations in MDS/AML patients.
